Bevacizumab and Tamoxifen are valid therapeutic options for metastatic breast cancer (mBC) patients. In this report, we describe a 47 year old woman with mBC successfully treated with a maintenance therapy with Bevacizumab+Tamoxifen. A maintenance approach using 2 different drugs with different targets and mechanism of action, such as anti-angiogenic and anti-hormonal treatment is particularly intriguing because they affect different pathways involved in mBC progression. Further studies including a large number of patients are needed, in order to select women who could benefit from this maintenance approach.
|Titolo:||Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer|
|Citazione:||Roviello, G., Francini, E., Perrella, A., Laera, L., Mazzei, M.A., Guerrini, S., et al. (2015). Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. CANCER BIOLOGY & THERAPY, 16(4), 493-497.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: